Research Summary

Jeroen is a methodologist working at the intersection of evidence synthesis, biostatistics, and health economics. He is a core faculty member with the UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), located in the Department of Clinical Pharmacy.

Jeroen has worked on research to understand the clinical and economic value of healthcare interventions. His research has frequently been conducted in the context of health technology assessment (HTA), with a focus on comparative effectiveness and cost-effectiveness. Prompted by the challenges encountered in applied research projects, Jeroen has performed methodological research. Notable contributions are the development of novel statistical methods to overcome the typical challenges in model-based cost-effectiveness evaluations characterized by gaps in the evidence base and complex evidence structures. Furthermore, Jeroen led initiatives to develop guidance for consumers and producers of network meta-analysis studies. He has promoted a more transparent and credible approach to model-based health economic evaluations and led the development of open-source simulation models to illustrate its feasibility. Jeroen has been involved in the ongoing development of an R software package to develop simulation models for health economic evaluations.

Jeroen’s current research interests are the clinical and economic value of precision medicine, incorporating health disparities in health economic modeling studies, and statistical methods for evidence synthesis.

Education

Faculty of Human Movement Sciences, Vrije Universiteit, Netherlands, MSc, 1998, Human Movement Sciences
Faculty of Medicine and Health Sciences, Erasmus University, Netherlands, MSc, 2001, Epidemiology
Faculty of Medicine and Health Sciences, Erasmus University, Netherlands, PhD, 2004, Epidemiology

Selected Publications

  1. Thom H, Leahy J, Jansen JP. Network Meta-analysis on Disconnected Evidence Networks When Only Aggregate Data Are Available: Modified Methods to Include Disconnected Trials and Single-Arm Studies while Minimizing Bias. Med Decis Making. 2022 May 07; 272989X221097081.  View on PubMed
  2. Jansen JP, Trikalinos TA, Phillips KA. Assessments of the Value of New Interventions Should Include Health Equity Impact. Pharmacoeconomics. 2022 05; 40(5):489-495.  View on PubMed
  3. Hong YD, Jansen JP, Guerino J, Berger ML, Crown W, Goettsch WG, Mullins CD, Willke RJ, Orsini LS. Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials. BMC Med. 2021 12 06; 19(1):307.  View on PubMed
  4. Rodriguez-Otero P, Ayers D, Cope S, Davies FE, Delforge M, Mojebi A, Jansen JP, Weisel K, Hege K, Dhanasiri S. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2021 10; 62(10):2482-2491.  View on PubMed
  5. Ortiz A, Kanters S, Hamed A, DasMahapatra P, Poggio E, Maski M, Aguiar M, Ponce E, Jansen JP, Ayers D, Goldgrub R. . Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. Clinical Kidney Journal. 2021; 4(14):1136-46.  View on PubMed
  6. Jones KM, Cook-Deegan R, Rotimi CN, Callier SL, Bentley AR, Stevens H, Phillips KA, Jansen JP, Weyant CF, Roberts DE, Zielinski D, Erlich Y, Garrison NA, Carroll SR, Ossorio PN, Moreau Y, Wang M. Complicated legacies: The human genome at 20. Science. 2021 02 05; 371(6529):564-569.  View on PubMed
  7. Popoff E, Besada M, Jansen JP, Cope S, Kanters S. Aligning text mining and machine learning algorithms with best practices for study selection in systematic literature reviews. Syst Rev. 2020 Dec 13; 9(1):293.  View on PubMed
  8. Keeping ST, Cope S, Chan K, Wilson FR, Jansen JP, Penrod JR, Abraham P, Camidge DR, Korytowsky B, Gu T, Garcia AJ, Le TK, Yuan Y. Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer. J Comp Eff Res. 2020 12; 9(18):1275-1284.  View on PubMed
  9. Incerti D, Hernandez EJM, Tkacz J, Jansen JP, Collier D, Gharaibeh M, Moore-Schiltz L, Stolshek BS. The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis. J Manag Care Spec Pharm. 2020 Oct; 26(10):1236-1242.  View on PubMed
  10. Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL. Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma". Biol Blood Marrow Transplant. 2020 12; 26(12):e335-e336.  View on PubMed
  11. Thom H, Jansen J, Shafrin J, Zhao L, Joseph G, Cheng HY, Gupta S, Shah N. Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis. BMJ Open. 2020 09 17; 10(9):e034147.  View on PubMed
  12. Goulding RE, Chenoweth M, Carter GC, Boye ME, Sheffield KM, John WJ, Leusch MS, Muehlenbein CE, Li L, Jen MH, Rojubally A, Jansen J, Druyts E. KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis. Cancer Treat Res Commun. 2020; 24:100200.  View on PubMed
  13. Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, Locke FL. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2020 09; 26(9):1581-1588.  View on PubMed
  14. Ortiz A, Kanters S, Hamed A, DasMahapatra P, Poggio E, Maski M, Aguiar M, Ponce E, Jansen JP, Ayers D, Goldgrub R, Desnick RJ. Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. Clin Kidney J. 2021 Apr; 14(4):1136-1146.  View on PubMed
  15. Jansen JP. Heterogeneity and subgroup analysis in network meta-analysis. In: Ting N, Cappelleri J, Ho S, Chen G. (editors). Design and analysis of subgroups with biopharmaceutical applications. Emerging topics in statistics and biostatistics. Springer, Cham. 2020; 369-385.  View on PubMed
  16. Cope S, Chan K, Jansen JP. Multivariate network meta-analysis of survival function parameters. Res Synth Methods. 2020 May; 11(3):443-456.  View on PubMed
  17. Cope S, Toor K, Popoff E, Fonseca R, Landgren O, Mateos MV, Weisel K, Jansen JP. Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma. Value Health. 2020 04; 23(4):441-450.  View on PubMed
  18. Sussell J, Silverstein AR, Goutam P, Incerti D, Kee R, Chen CX, Batty DS, Jansen JP, Kasiske BL. The economic burden of kidney graft failure in the United States. Am J Transplant. 2020 05; 20(5):1323-1333.  View on PubMed
  19. Jansen JP, Incerti D, Linthicum MT. Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project. Pharmacoeconomics. 2019 11; 37(11):1313-1320.  View on PubMed
  20. Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8. Adv Ther. 2019 11; 36(11):2982-2985.  View on PubMed

Go to UCSF Profiles, powered by CTSI